Coverage of HIV Drug Therapy Glasgow 2016
- Details
- Category: HIV Treatment
- Published on Friday, 04 November 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 International Congress on Drug Therapy in HIV Infection, held October 23-26, 2016, in Glasgow, Scotland.
Conference highlights include new antiretroviral therapies and strategies, HIV prevention, HIV-related comorbidities, and expanding access to treatment.
Full listing of coverage by topic
11/4/16
HIV Drug Therapy: Lower-dose Efavirenz Equally Effective with Fewer Side Effects
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 23 December 2014 00:00
- Written by Liz Highleyman
A reduced dose of efavirenz (Sustiva or Stocrin) for first-line HIV therapy suppressed viral load as well as the standard dose, but was associated with fewer characteristic side effects, researchers reported at the recent HIV Drug Therapy 2014 meeting in Glasgow. A related study found that half the dose maintained viral suppression in people with high efavirenz levels in their blood.
Complete Coverage of HIV Drug Therapy 2014
- Details
- Category: HIV Treatment
- Published on Thursday, 13 November 2014 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the HIV Drug Therapy 2014 Conference Research, November 2-6, 2014, in Glasgow, Scotland.
Full listing of coverage by topic
11/4/14
HIV Drug Therapy: Efavirenz Not Linked to Higher Suicide Risk in D:A:D Cohort
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 09 December 2014 00:00
- Written by Liz Highleyman
People taking antiretroviral therapy (ART) regimens containing the NNRTI efavirenz (Sustiva) were not more likely to die due to suicide or psychiatric illness than those taking other drugs in the large D:A:D cohort, researchers reported last month at the HIV Drug Therapy 2014 meeting in Glasgow.
HIV Drug Therapy: Once-daily Dolutegravir Superior to Darunavir at 96 Weeks
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 13 November 2014 00:00
- Written by Alain Volny-Anne
Treatment with a triple antiretroviral combination containing the once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported this month at the HIV Drug Therapy Glasgow conference.
More Articles...
- HIV Drug Therapy: Darunavir/Ritonavir Protease Inhibitor Monotherapy Less Effective than 3-Drug ART
- HIV Drug Therapy: Doravirine Works as Well as Efavirenz with Fewer CNS Side Effects
- HIV Drug Therapy: Truvada PrEP Use Rising, Especially Among Men
- HIV Drug Therapy: Australia Performs Best in HIV Treatment Cascade -- 62% Undetectable Viral Load
- HIV Drug Therapy: Do Emtricitabine and Lamivudine Have Similar Efficacy for First-line ART?
- HIV Drug Therapy: Efavirenz Compromises Hormonal Contraceptive Implant
Web Design and Development by